A5012732516- Nanoplatforms for cancer theranostics
- Nanoparticle-Based Drug Delivery
- Inflammatory Bowel Disease
- Vestibular and auditory disorders
- Advanced Polymer Synthesis and Characterization
- RNA Interference and Gene Delivery
- Pharmaceutical studies and practices
- Dendrimers and Hyperbranched Polymers
- Adolescent and Pediatric Healthcare
- Polymer Surface Interaction Studies
- Molecular Sensors and Ion Detection
- Cerebral Venous Sinus Thrombosis
- Healthcare Systems and Public Health
- Cancer Immunotherapy and Biomarkers
- Medical and Biological Sciences
- Hearing, Cochlea, Tinnitus, Genetics
- Advanced biosensing and bioanalysis techniques
- Analytical Chemistry and Sensors
- Advanced Nanomaterials in Catalysis
- Immune cells in cancer
- Natural product bioactivities and synthesis
- Conducting polymers and applications
- Metal complexes synthesis and properties
- Advanced Sensor and Energy Harvesting Materials
- Natural Compounds in Disease Treatment
Sun Yat-sen University
2019-2025
The Seventh Affiliated Hospital of Sun Yat-sen University
2024-2025
Janssen (United States)
2024
South China Normal University
2016
Abstract As the second most common cause of cancer‐related death worldwide, colorectal cancer (CRC) requires novel therapy strategies. Biodegradable polymers are used as drug carriers for treating CRC and other cancers. However, one limitations polymeric is that they do not directly involve procedure. Herein, to develop a delivery system with additional therapeutic effect from polymer itself, poly(ursolic acid) (PUA) is, first time, simply synthesized via polycondensation ursolic acid (UA),...
Immunotherapy as an alternative treatment strategy for B-cell lymphoma is undesirable because of tumor heterogeneity and immune surveillance. Spermidine (SPM), a regulator the microenvironment (TME), can facilitate release damage-associated molecular patterns (DAMPs) from cancer cells, promote recognition, thus alleviate surveillance in TME. Hence, this work, self-assembled spermidine-based metal-immunopeptide nanocomplexes (APP-Fe NCs; APP anti-programmed death ligand-1 peptide) with...
The nanoassemblies of Dex<sub>6k</sub>–BSA–PTX and the pH-responsive drug release for anti-tumor applications<italic>in vivo</italic>.
Poly(disulfide)s-based systems with repetitive disulfide bonds in their backbones are emerging as promising tumor microenvironment responsive platforms for drug delivery. However, complicated synthesis and purification processes have restricted further application. Herein, we developed redox-responsive poly(disulfide)s (PBDBM) by one-step oxidation polymerization of a commercially available monomer, 1,4-butanediol bis(thioglycolate) (BDBM). PBDBM can self-assemble...
Prostate cancer (PCa) with a high incidence worldwide is serious threat to men's health. Despite the continuous development of treatment strategies for PCa in recent years, long-term prognosis patients still poor. Hence, discovery and novel, secure, efficient therapeutic approaches hold significant clinical significance. Although sorafenib (SOR) displays potential as option PCa, its efficacy hindered by drug resistance, limited water solubility, rapid metabolism. Therefore, we proposed...
Abstract Polybromo‐1 (PBRM1) serves as a crucial regulator of gene transcription in various tumors, including intrahepatic cholangiocarcinoma (iCCA). However, the exact role PBRM1 iCCA and mechanism by which it regulates downstream target genes remain unclear. This research has revealed that is significantly downregulated tissues, this reduced expression linked to aggressive clinicopathological features poor prognosis. Furthermore, demonstrated can impede progression, therapy nanomedicine...
Abstract Background Treatment of paediatric patients (pts) with Crohn’s disease (CD) can offer some challenges to providers. There is an urgent need inform prescribers about efficacy, safety, and dosing. REALITI evaluated the effectiveness safety ustekinumab (UST) routine clinical care in pts (age 2 &lt;18) regardless severity or baseline corticosteroid use. Reference data are shown for young adults 18 25) CD, whom UST approved. Data were obtained from ImproveCareNow (ICN) Registry....
Abstract Background Few approved treatment options exist for paediatric patients (pts) with Crohn’s disease (CD). Paediatric inflammatory bowel (IBD) medication approvals are delayed nearly 7 years after adult approvals,1 resulting in off-label use and potential incorrect dosing. The REALITI Study evaluated the effectiveness safety of ustekinumab (UST) routine clinical care pts (age 2-&lt;18) young adults 18-25) moderately to severely active CD (Short activity [sPCDAI] score ≥30) using...